Literature DB >> 22147810

Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users.

Christina R Di Iorio1, Tristan J Watkins, Mary S Dietrich, Aize Cao, Jennifer U Blackford, Baxter Rogers, Mohammed S Ansari, Ronald M Baldwin, Rui Li, Robert M Kessler, Ronald M Salomon, Margaret Benningfield, Ronald L Cowan.   

Abstract

CONTEXT: MDMA (3,4-methylenedioxymethamphetamine, also popularly known as "ecstasy") is a popular recreational drug that produces loss of serotonin axons in animal models. Whether MDMA produces chronic reductions in serotonin signaling in humans remains controversial.
OBJECTIVE: To determine whether MDMA use is associated with chronic reductions in serotonin signaling in the cerebral cortex of women as reflected by increased serotonin(2A) receptor levels.
DESIGN: Cross-sectional case-control study comparing serotonin(2A) receptor levels in abstinent female MDMA polydrug users with those in women who did not use MDMA (within-group design assessing the association of lifetime MDMA use and serotonin(2A) receptors). Case participants were abstinent from MDMA use for at least 90 days as verified by analysis of hair samples. The serotonin(2A) receptor levels in the cerebral cortex were determined using serotonin(2A)-specific positron emission tomography with radioligand fluorine 18-labeled setoperone as the tracer.
SETTING: Academic medical center research laboratory. PARTICIPANTS: A total of 14 female MDMA users and 10 women who did not use MDMA (controls). The main exclusion criteria were nondrug-related DSM-IV Axis I psychiatric disorders and general medical illness. MAIN OUTCOME MEASURES: Cortical serotonin(2A) receptor nondisplaceable binding potential (serotonin(2A)BP(ND)).
RESULTS: MDMA users had increased serotonin(2A)BP(ND) in occipital-parietal (19.7%), temporal (20.5%), occipitotemporal-parietal (18.3%), frontal (16.6%), and frontoparietal (18.5%) regions (corrected P < .05). Lifetime MDMA use was positively associated with serotonin(2A)BP(ND) in frontoparietal (β = 0.665; P = .007), occipitotemporal (β = 0.798; P = .002), frontolimbic (β = 0.634; P = .02), and frontal (β = 0.691; P = .008) regions. In contrast, there were no regions in which MDMA use was inversely associated with receptor levels. There were no statistically significant effects of the duration of MDMA abstinence on serotonin(2A)BP(ND).
CONCLUSIONS: The recreational use of MDMA is associated with long-lasting increases in serotonin(2A) receptor density. Serotonin(2A) receptor levels correlate positively with lifetime MDMA use and do not decrease with abstinence. These results suggest that MDMA use produces chronic serotonin neurotoxicity in humans. Given the broad role of serotonin in human brain function, the possibility for therapeutic MDMA use, and the widespread recreational popularity of this drug, these results have critical public health implications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147810      PMCID: PMC3538835          DOI: 10.1001/archgenpsychiatry.2011.156

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  88 in total

1.  Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study.

Authors:  John Karageorgiou; Mary S Dietrich; Evonne J Charboneau; Neil D Woodward; Jennifer U Blackford; Ronald M Salomon; Ronald L Cowan
Journal:  Neuroimage       Date:  2009-03-02       Impact factor: 6.556

2.  Gender, personality, and serotonin-2A receptor binding in healthy subjects.

Authors:  Paul H Soloff; Julie C Price; Neale Scott Mason; Carl Becker; Carolyn C Meltzer
Journal:  Psychiatry Res       Date:  2010-01-30       Impact factor: 3.222

3.  Neuroimaging in human MDMA (Ecstasy) users.

Authors:  Ronald L Cowan; Deanne M Roberts; James M Joers
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

4.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

5.  Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study.

Authors:  Neil D Woodward; David H Zald; Zhaohua Ding; Patrizia Riccardi; M Sib Ansari; Ronald M Baldwin; Ronald L Cowan; Rui Li; Robert M Kessler
Journal:  Neuroimage       Date:  2009-02-05       Impact factor: 6.556

Review 6.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

7.  Effects of MDMA on sociability and neural response to social threat and social reward.

Authors:  Gillinder Bedi; K Luan Phan; Mike Angstadt; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2009-08-13       Impact factor: 4.530

8.  Midbrain dopamine receptor availability is inversely associated with novelty-seeking traits in humans.

Authors:  David H Zald; Ronald L Cowan; Patrizia Riccardi; Ronald M Baldwin; M Sib Ansari; Rui Li; Evan S Shelby; Clarence E Smith; Maureen McHugo; Robert M Kessler
Journal:  J Neurosci       Date:  2008-12-31       Impact factor: 6.167

9.  MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study.

Authors:  V Raj; H C Liang; N D Woodward; A L Bauernfeind; J Lee; M S Dietrich; S Park; R L Cowan
Journal:  J Psychopharmacol       Date:  2009-03-20       Impact factor: 4.153

10.  Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits.

Authors:  Joshua W Buckholtz; Michael T Treadway; Ronald L Cowan; Neil D Woodward; Stephen D Benning; Rui Li; M Sib Ansari; Ronald M Baldwin; Ashley N Schwartzman; Evan S Shelby; Clarence E Smith; David Cole; Robert M Kessler; David H Zald
Journal:  Nat Neurosci       Date:  2010-03-14       Impact factor: 24.884

View more
  11 in total

1.  fNIRS suggests increased effort during executive access in ecstasy polydrug users.

Authors:  C A Roberts; C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2014-11-14       Impact factor: 4.530

Review 2.  Brain serotonin function in MDMA (ecstasy) users: evidence for persisting neurotoxicity.

Authors:  Margaret M Benningfield; Ronald L Cowan
Journal:  Neuropsychopharmacology       Date:  2013-01       Impact factor: 7.853

Review 3.  The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Authors:  Yosta Vegting; Liesbeth Reneman; Jan Booij
Journal:  Psychopharmacology (Berl)       Date:  2016-08-28       Impact factor: 4.530

4.  Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization.

Authors:  Michael D Berquist; Sebastian Leth-Petersen; Jesper Langgaard Kristensen; William E Fantegrossi
Journal:  Psychopharmacology (Berl)       Date:  2019-11-15       Impact factor: 4.530

5.  Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing.

Authors:  Tristan J Watkins; Vidya Raj; Junghee Lee; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Ronald M Salomon; Sohee Park; Margaret M Benningfield; Christina R Di Iorio; Ronald L Cowan
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

Review 6.  Oscillatory serotonin function in depression.

Authors:  Ronald M Salomon; Ronald L Cowan
Journal:  Synapse       Date:  2013-05-21       Impact factor: 2.562

7.  3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity.

Authors:  Elisabet Cuyas; Patricia Robledo; Nieves Pizarro; Magí Farré; Elena Puerta; Norberto Aguirre; Rafael de la Torre
Journal:  Neurotox Res       Date:  2013-08-15       Impact factor: 3.911

Review 8.  Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Authors:  Hans Emanuel Oeri
Journal:  J Psychopharmacol       Date:  2020-09-10       Impact factor: 4.153

9.  Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users.

Authors:  Oliver G Bosch; Michael Wagner; Frank Jessen; Kai-Uwe Kühn; Alexius Joe; Erich Seifritz; Wolfgang Maier; Hans-Jürgen Biersack; Boris B Quednow
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

Review 10.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.